Literature DB >> 12483443

Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion.

M Law1, D E Meltzer, S Cha.   

Abstract

Tumefactive demyelinating lesions can present with features similar, clinically and radiologically, to those of brain tumours. Proton MR spectroscopy has been increasingly used to characterize intracranial pathology. As the underlying pathophysiology of neoplasms is different from that of demyelinating disease, one may expect the metabolic composition of neoplasms to be significantly different from that of demyelinating lesions. We report a 49-year-old woman in whom the neurologic and radiologic findings were highly suggestive of a high-grade brain tumor, and the spectroscopic features were sufficiently similar to that of a tumor to convince the neurosurgeon to operate. This case emphasizes the need for caution when confronted with a patient who presents with a differential diagnosis of demyelinating lesion versus neoplasm.

Entities:  

Mesh:

Year:  2002        PMID: 12483443     DOI: 10.1007/s00234-002-0872-1

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  17 in total

Review 1.  Recent advances in magnetic resonance neurospectroscopy.

Authors:  Yael Rosen; Robert E Lenkinski
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 2.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

Review 3.  Energy failure in multiple sclerosis and its investigation using MR techniques.

Authors:  David Paling; Xavier Golay; Claudia Wheeler-Kingshott; Raju Kapoor; David Miller
Journal:  J Neurol       Date:  2011-06-10       Impact factor: 4.849

4.  Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Authors:  Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei
Journal:  Neurol Sci       Date:  2016-04-15       Impact factor: 3.307

Review 5.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

6.  Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.

Authors:  A Cianfoni; S Niku; S G Imbesi
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

Review 7.  Schilder's disease: non-invasive diagnosis? :A case report and review.

Authors:  Susanna Bacigaluppi; Gabriele Polonara; Mario L Zavanone; Rolando Campanella; Vincenzo Branca; Sergio M Gaini; Giovanni Tredici; Antonella Costa
Journal:  Neurol Sci       Date:  2009-07-17       Impact factor: 3.307

Review 8.  Quantitative imaging biomarkers in neuro-oncology.

Authors:  Adam D Waldman; Alan Jackson; Stephen J Price; Christopher A Clark; Thomas C Booth; Dorothee P Auer; Paul S Tofts; David J Collins; Martin O Leach; Jeremy H Rees
Journal:  Nat Rev Clin Oncol       Date:  2009-06-23       Impact factor: 66.675

Review 9.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 10.  Perfusion MRI: the five most frequently asked clinical questions.

Authors:  Marco Essig; Thanh Binh Nguyen; Mark S Shiroishi; Marc Saake; James M Provenzale; David S Enterline; Nicoletta Anzalone; Arnd Dörfler; Àlex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.